Source comparison
CJC-1295 no DAC & Ipamorelin SubQ vs IM: Route Comparison
Absorption Rate Gradual lymphatic uptake; Tmax 45–75 min Rapid vascular absorption; Tmax 20–35 min SubQ extends effective window; IM produces sharper pulse SubQ aligns better with CJC-1295's sustained-release design Peak Plasma Concentration (Cmax) 25–40% lowe
This comparison does not assign a generated winner or score.
- Absorption Rate
- Gradual lymphatic uptake; Tmax 45–75 min
- Rapid vascular absorption; Tmax 20–35 min
- SubQ extends effective window; IM produces sharper pulse
- SubQ aligns better with CJC-1295's sustained-release design
- Peak Plasma Concentration (Cmax)
- 25–40% lower than IM
- 25–40% higher than SubQ
- IM creates higher transient levels; total exposure (AUC) equivalent
- Peak height matters less than duration above receptor threshold
- Duration Above Threshold
- 18–22% longer than IM
- Shorter effective window
- SubQ maintains receptor occupancy longer per dose
- Particularly relevant for protocols targeting overnight GH secretion
- Injection Discomfort
- Minimal; smaller needle, less tissue trauma
- Moderate; deeper penetration, muscle sensitivity
- SubQ improves adherence in long-term protocols
- Pain is a protocol adherence risk. SubQ reduces dropout
- Site Reaction Frequency
- 8–12% (mild erythema)
- 15–22% (soreness, induration)
- IM triggers more localized immune response
- Lower inflammation = more consistent repeat dosing
- Technical Skill Required
- Low; self-administration feasible
- Moderate; depth control critical
- SubQ allows reliable self-injection without training
- Practical consideration for independent research settings